SUMMARY Two patients who developed painless jaundice while taking sulindac are described. Rechallenge in one case confirmed the association of hepatic damage with sulindac administration. Laboratory data and liver biopsy findings suggested a hepatitis with cholestatic features.
Sulindac is a recently introduced non-steroidal anti-inflammatory drug which has been associated with hepatocellular damage in three published cases. [1] [2] [3] We present here two cases of clinical jaundice associated with the use of sulindac. In one case both the serum transaminases and alkaline phosphatase were moderately raised. Rechallenge with sulindac caused transaminase levels to rise within 24 hours. In the other case, the predominant clinical and laboratory findings were those of cholestasis, a pattern not previously reported.
Case 1
A 70-year-old caucasian woman with a long history of osteoarthritis involving the knees, hips, back, and shoulders was admitted to the Toronto Western Hospital Surgical Service with jaundice in January 1980. The patient had been using dimethylsulphoxide (DMSO) cutaneously for over a year. Ten days before admission she was given oral sulindac.
Four days later she developed nausea, vomiting, malaise, and a fever (38°C). A day later, she visited her family doctor and jaundice was noted. The patient was treated with ampicillin, propanthelin, and maalox antacid. Because of persisting jaundice she was admitted to hospital. Notably, she denied alcohol use, was not taking any other medications, and gave no history of exposure to hepatitis.
Physical examination disclosed an afebrile, mildly jaundiced woman with a normal liver span. Laboratory data revealed a normal haemogram, * Address for reprint requests: Jenny Heathcote. as above.
Received for publication 4 January 1982 while the liver tests showed: SGOT 211 IU/l (NR 0-40), alkaline phosphatase 325 IU/l (NR 20-100 IU/l), bilirubin 54 gm/l (3.2 mg/dl), albumin 4-0 g/dl, globulin 2-9 g/dl, prothrombin time and partial thromboplastin time normal. An ultrasound of the liver, biliary tree, and pancreas was normal, as was an intravenous cholangiogram and endoscopic retrograde cholangiopancreatatography.
All her medications were withdrawn on admission. Once a surgical cause for her jaundice had been excluded, a liver biopsy was performed. This was carried out 15 days after admission. This showed normal liver parenchyma except for a prominence of ceroid pigment within Kupffer cells in the centrilobular zone III areas (Fig. 1 normal. Hepatitis markers were negative. Ultra-There are numerous Kupffer cells containing ceroidpigment sound examination of the liver, biliary tree, and (curvedarrows). Dilated canaliculi, often containing bile pancreas was normal as was an ERCP. It was seven plus, were numerous (straight arrows). PAS-diastase stain months before the patient became anicteric and her x330 (original magnification).
reversible hepatic dysfunction with sulindac. Case 1 is similar to previous reports with regard to the biochemical presentation. Case 2, however, demonstrated a predominantly cholestatic picture. Both our patients developed malaise and jaundice. Extrahepatic obstruction was initially suspected and ruled out. It is unlikely that DMSO (which may cause liver enzyme abnormalities4) was responsible for the findings in case 1, as the drug was continued while the liver tests returned to normal.
There has been no previous detailed report of the liver biopsy findings in sulindac hepatotoxicity. Both our cases showed prominent pigmented Kupffer cells in zone III. In addition, case 2 had dilated bile canaliculi and evidence of mild hepatocellular necrosis, also in zone III. The biopsies were performed two weeks after discontinuing the drug and yet both provided patterns consistent with drug-induced injury and unlike those associated with extrahepatic obstruction. The relative absence of inflammatory cell infiltration may be related to the delay before biopsy.
Sulindac has now been associated with both hepatitic and cholestatic liver disease. The mechanism of hepatotoxicity is unknown. Symptomatic complaints occurred anywhere from one week to two months after initiation of sulindac therapy. In all cases described so far the liver enzymes returned to normal within a month of stopping sulindac. Case 2 in this report was unusual, as her jaundice persisted for several months. Both our patients were otherwise healthy, but two of the three previously described cases had systemic diseases (juvenile rheumatoid arthritis1 and systemic lupus3). In the two cases where rechallenge occurred, the rapid appearance of symptoms and liver test abnormalities (less than 24 hours) suggests a hypersensitivity reaction and probably confirms an aetiological relationship.
In summary, we have presented two cases of liver damage associated with the use of sulindac. Clinically, the patients presented with painless jaundice. Recognition of the association of cholestasis with sulindac may prevent unnecessary laparotomy or invasive investigation in the jaundiced patient.
